A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice

Hoffmann-La Roche8 enrolled

Overview

This is a single-arm, open-label, non-randomized, multicenter trial to evaluate the efficacy and safety of using tocilizumab for confirmed rheumatoid arthritis participants in clinical practice.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

No interventionOTHER

No intervention administered in this study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with moderate-to-severe active rheumatoid arthritis (RA) for over 3 months * Started on tocilizumab, with or without previous history of biological treatment Exclusion Criteria: * Pregnant or lactating women * Treated with an investigational drug within 30 days prior to initiation of study drug * Having a condition that, in the opinion of the investigator, could compromise the participant's safety or interfere with the study results

Locations (2)

King Khaled Uni Hospital; Oncology

Riyadh, Saudi Arabia

King Fahad Medical City; Gastroentrology

Riyadh, Saudi Arabia

Outcomes

Primary Outcomes

Percentage of Participants with a 28-Joint Disease Activity Score (DAS28) < 2.6 at Week 24

Time frame: Week 24

Number of Participants with Adverse Events

Time frame: Up to 30 months

Secondary Outcomes

Percentage of Participants with Tender Joint Count-28 Joints (TJC28) < or = 1 at Week 12 and Week 24